Nektar Therapeutics (NKTR) Earnings Call Presentation

Phase 2b REZOLVE-AD Topline Results from 16-Week Induction Rezpegaldesleukin in Patients with Moderate-to- Severe Atopic Dermatitis June 24, 2025 1 Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Nektar Therapeutics (the "Company" or "Nektar")'s plans, progress, and timing ...